{"preliminary_commentary":{"by_channel":{"x_thread":6},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":false},"commentary_summary":null,"drugs_tested":[["olomorasib","pembrolizumab"],["olomorasib","durvalumab"]],"indication":"stage II-III KRAS G12C-mutant non-small cell lung cancer","name":"SUNRAY-02","nct_id":"NCT06890598","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=sunray-02-nct06890598. The price is an estimate of verified statements from the commentary indexed so far. Final coverage is set when the report is built. You never pay more than quoted: if the report is delivered at a smaller size, you pay that size's price, and anything paid above it is refunded. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_rule":"Never more than quoted: the buyer pays the smaller of price_usd and the price the delivered edition is sold at.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":"SUNRAY-02","arms":[{"description":"Participants will receive olomorasib administered orally in combination with pembrolizumab intravenously (IV) for up to 1 year followed by olomorasib alone for up to 3 years of total treatment.","label":"Part A: Olomorasib + Pembrolizumab","type":"EXPERIMENTAL"},{"description":"Participants will receive placebo administered orally in combination with pembrolizumab administered IV for up to 1 year followed by placebo alone for up to 3 years of total treatment.","label":"Part A: Placebo + Pembrolizumab","type":"PLACEBO_COMPARATOR"},{"description":"Participants will receive olomorasib administered orally in combination with durvalumab administered IV for up to 1 year followed by olomorasib alone for up to 3 years of total treatment.","label":"Part B: Olomorasib + Durvalumab","type":"EXPERIMENTAL"},{"description":"Participants will receive placebo administered orally in combination with durvalumab administered IV for up to 1 year followed by placebo alone for up to 3 years of total treatment.","label":"Part B: Placebo + Durvalumab","type":"PLACEBO_COMPARATOR"}],"collaborators":["AstraZeneca"],"completion_date":{"date":"2032-02","type":"ESTIMATED"},"conditions":["Carcinoma, Non-Small-Cell Lung"],"enrollment":{"count":700,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"Olomorasib","otherNames":["LY3537982"],"type":"DRUG"},{"name":"Pembrolizumab","otherNames":[],"type":"DRUG"},{"name":"Durvalumab","otherNames":[],"type":"DRUG"},{"name":"Placebo","otherNames":[],"type":"DRUG"}],"last_update":"2026-11-04","lead_sponsor":"Eli Lilly and Company","official_title":"A Phase 3, Multicenter, Double-Blind, Placebo-controlled Study Assessing the Efficacy and Safety of Olomorasib in Combination With Standard of Care Immunotherapy in Participants With Resected or Unresectable KRAS G12C-Mutant, Non-Small Cell Lung Cancer - SUNRAY-02","overall_status":"RECRUITING","phases":["PHASE3"],"primary_completion_date":{"date":"2029-05","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Part A: Disease-Free Survival (DFS) by Investigator Assessment","timeFrame":"Randomization to disease recurrence or death from any cause (Estimated as approximately 4 years)."},{"measure":"Part B: Progression-Free Survival (PFS) by BICR","timeFrame":"Randomization to disease progression or death from any cause (Estimated as approximately 3 years)."}],"references":[{"citation":"Chaft J, Lee JM, Senan S, Neal JW, Nadal E, Negrao MV, Popat S, Garassino MC, Gray JE, Lee SH, Mazieres J, Thomas M, Benes M, Liu H, Liu J, Ma QL, Segall G, Puri T, Wu YL. SUNRAY-02: a study of olomorasib combined with immunotherapy in stage II-III KRAS G12C-mutant non-small cell lung cancer after definitive therapy. Future Oncol. 2026 Oct 1:1-10. doi: 10.1080/14796694.2026.2736401. Online ahead of print.","pmid":"42823821","type":"DERIVED"}],"start_date":{"date":"2025-03-27","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer","url":"https://clinicaltrials.gov/study/NCT06890598"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.2","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/sunray-02-nct06890598"}